The mpn Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mpn Hub cannot guarantee the accuracy of translated content. The mpn and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mpn content recommended for you
JAK 2V617F molecular response and event-free survival in an early polycythemia vera population
|
During the European Hematology Association Hybrid Congress 2024, Jean-Jacques Kiladjian delivered a presentation on the correlation between JAK2V617F molecular response (MR) and event-free survival (EFS) in early polycythemia vera (PV).1 The final data from the phase III PROUD-PV and CONTINUATION-PV trials were used to assess this correlation, as well as the impact of ropeginterferon (ropeg) alfa-2b on EFS.1 |
| Key learnings1 |
|
The probability of EFS during the study periods was significantly higher in patients who experienced a MR at a hazard ratio (HR) of 0.24 (95% confidence interval [CI], 0.07–0.83; p = 0.02). |
|
Time spent in MR was higher in patients treated with ropeg alfa-2b compared with hydroxyurea or best available therapy (BAT) at 66.7% vs 8.4%, respectively (p = 0.01). |
|
A higher JAK2V617F allele burden was associated with an increased risk of events at an HR of 1.042 (95% CI, 1.023–1.062; p = 0.0001), equating to 4.2% increased risk of events per 1% increase in variant allele frequencies. |
|
These data suggest that a 10% decrease in allele burden could correspond with a 34% decreased risk of events. |
|
Treatment with ropeg alfa-2b was associated with higher rates of <1% JAK2V617F allele burden, achieved in 20.7% of patients compared with 1.4% in the control arm (p = 0.0001). |
| Overall, findings from these trials suggest that there is a correlation between MR and EFS, as well as JAK2V617F and EFS, both of which could be extended with the use of ropeg alfa-2b. |
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
